vIndianz.com (Aug. 15, 2009) — Drugmaker GlaxoSmithKline says it has started testing its swine flu vaccine in humans. The company has already received orders for more than 96 million doses of vaccine for H1N1 swine flu in the past two weeks.
UK drug manufacturer GlaxoSmithKline plans to conduct 16 clinical trials of its swine flu vaccine in more than 9,000 people in Europe, Canada and the United States.
Glaxo said the first trial of its swine flu vaccine in Germany of adults ages 18 to 60. Those data will be shared with drug regulatory authorities so they can make an early decision whether to license the vaccine.
Both Europe and the U.S. have fast-track approval systems for the swine flu vaccine.
Two other major drugmakers, Novartis and Sanofi-Aventis, began testing their swine flu vaccines earlier this month.
The United States has also ordered $250 million worth of vaccine ingredients. The company says it will donate 50 million doses of swine flu vaccine to the World Health Organization for use in poorer countries.
The World Health Organization (WHO) declared H1N1 flu a pandemic earlier this year. Since swine flu emerged in April, it has killed at least 1,462 people worldwide.
Further Reading- The Great Flu Video Game can Save World from New Pandemic
- Sugary drinks can lead to blood pressure
- Obama to visit India this year
- Anthrax vaccine mission put to an end over animal rights
- World Bank bars Siemens’ division for 4 years
- Swine Flu vs. Seasonal Flu
- Website Wikileaks releases ‘9/11 messages’
- Google Project 10^100 update ‘within a month’
- U.A.E Pledge calms and cools markets down but Dubai fears continue
- Poll: Enormous majority of Israelis in opposition to fur industry
Stay updated! Follow us on twitter and subscribe to our feed via Feedburner.
Loading ...
No Comments